ArticleOncogene2007
Protective roles of quinone reductase and tamoxifen against estrogen-induced mammary tumorigenesis.
Article in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- The impact of estrogen on benign breast tumors and exploration of recurrence mechanisms.Frontiers in oncology · 2025Review
- Inhibitory Effects of γ- and δ-Tocopherols on Estrogen-Stimulated Breast CancerCancer prevention research (Philadelphia, Pa.) · 2017Article
- Modulatory Effect of Fermented Papaya Extracts on Mammary Gland Hyperplasia Induced by Estrogen and Progestin in Female Rats.Oxidative medicine and cellular longevity · 2017Article
- The molecular etiology and prevention of estrogen-initiated cancers: Ockham's Razor: Pluralitas non est ponenda sine necessitate. Plurality should not be posited without necessity.Molecular aspects of medicine · 2014Review
- Antioxidant-mediated up-regulation of OGG1 via NRF2 induction is associated with inhibition of oxidative DNA damage in estrogen-induced breast cancer.BMC cancer · 2013Article
- MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis.Carcinogenesis · 2013Article
- Selective estrogen receptor modulator BC-1 activates antioxidant signaling pathway in vitro via formation of reactive metabolites.Acta pharmacologica Sinica · 2013Article
- Total antioxidant status in plasma of breast cancer patients in relation to ERβ expression.Contemporary oncology (Poznan, Poland) · 2013Article
- Aberrant Keap1 methylation in breast cancer and association with clinicopathological features.Epigenetics · 2013Article
- Superoxide dismutase 3 is induced by antioxidants, inhibits oxidative DNA damage and is associated with inhibition of estrogen-induced breast cancer.Carcinogenesis · 2012Article
- Induction of quinone reductase by tamoxifen or DPN protects against mammary tumorigenesis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2012Article
- Induction of NAD(P)H-quinone oxidoreductase 1 by antioxidants in female ACI rats is associated with decrease in oxidative DNA damage and inhibition of estrogen-induced breast cancer.Carcinogenesis · 2012Article
- TARGETING THE GENOTOXIC EFFECTS OF ESTROGENS.Drug discovery today. Disease mechanisms · 2012Article
- The etiology and prevention of breast cancer.Drug discovery today. Disease mechanisms · 2012Article
- Article
- Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer.The Journal of steroid biochemistry and molecular biology · 2011Review
- Article
- Resveratrol and N-acetylcysteine block the cancer-initiating step in MCF-10F cells.Free radical biology & medicine · 2011Article
- Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer.Breast cancer research and treatment · 2010Article
- NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector.Archives of biochemistry and biophysics · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
We previously reported that antiestrogen-liganded estrogen receptor beta (ERbeta) transcriptionally activates the major detoxifying enzyme quinone reductase (QR) (NAD(P)H:quinone oxidoreductase). Further studies on the functional role of ERbeta-mediated upregulation of antioxidative enzymes indicated protective effects against estrogen-induced oxidative DNA damage (ODD). We now report on in vivo and in vitro studies that show that ERbeta-mediated upregulation of QR are involved in the protection against estrogen-induced mammary tumorigenesis. Using the August Copenhagen Irish (ACI) model of estrogen-induced carcinogenesis, we observed that increased ODD and decreased QR expression occur early in the process of estrogen-induced mammary tumorigenesis. Prevention of ACI mammary gland tumorigenesis by tamoxifen was accompanied by decreased ODD and increased QR levels. These correlative findings were supported by our findings that downregulation of QR levels led to increased levels of estrogen quinone metabolites and enhanced transformation potential of 17beta-estradiol treated MCF10A non-tumorigenic breast epithelial cells. Concurrent expression of ERbeta and treatment with 4-hydroxytamoxifen decreased tumorigenic potential of these MCF10A cells. We conclude that upregulation of QR, through induction by tamoxifen, can inhibit estrogen-induced ODD and mammary cell tumorigenesis, representing a possible novel mechanism of tamoxifen prevention against breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.